Mirum Pharmaceuticals Inc.

MIRM

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Rock Springs Capital Perceptive Advisors BVF Partners

Position Trend

Feb 13, 2026

$165.4M

1 fund

Feb 17, 2026

$379.5M

4 funds

+130% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 762,294Value: $60.2M

# Signal Note: Rock Springs Capital Initiates $60.2M Position in MIRM Rock Springs' substantial new position in Mirum suggests conviction in the company's late-stage pipeline, likely centered on **maralixibat for progressive familial intrahepatic cholestasis (PFIC)**, which has shown clinical efficacy in reducing pruritus and bile acid levels in pediatric patients. The timing aligns with anticipated regulatory catalysts, including potential FDA feedback or label expansion discussions, though near-term catalysts should be monitored against cash runway and partnership developments. This concentrated bet reflects a high-conviction thesis on a rare disease asset with limited competitive alternatives.

Perceptive AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

KYMR5 funds RVMD5 funds OLMA4 funds DXCM4 funds ISRG4 funds BSX4 funds IRON4 funds NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Perceptive Advisors Initiates MIRM Position Edelman's $20.5M entry into Mirum likely reflects conviction in maralixibat's commercial potential for progressive familial intrahepatic cholestasis (PFIC), following FDA approval in December 2023 and ramp-up execution through 2024. The position timing suggests confidence in near-term revenue inflection and potential label expansions (alagille syndrome data expected in coming quarters) that could validate the rare hepatic disease thesis. This represents Perceptive's typical pattern of backing clinical-stage wins transitioning to commercialization phases.